Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2
Status:
Withdrawn
Trial end date:
1997-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF)
buprenorphine/naloxone combination tablet administration and determine whether outcomes are
improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in
which take-home doses are given on intervening days.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Heroin Naloxone